[HTML][HTML] Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

O Abani, A Abbas, F Abbas, M Abbas, S Abbasi… - The Lancet, 2021 - thelancet.com
Background Many patients with COVID-19 have been treated with plasma containing anti-
SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent
plasma therapy in patients admitted to hospital with COVID-19. Methods This randomised,
controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy
[RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-
19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and …

[HTML][HTML] Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background Many patients with COVID-19 have been treated with plasma containing anti-
SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent
plasma therapy in patients admitted to hospital with COVID-19. Methods This randomised,
controlled, open-label, platform trial (Randomised Evaluation of COVID-19 Therapy
[RECOVERY]) is assessing several possible treatments in patients hospitalised with COVID-
19 in the UK. The trial is underway at 177 NHS hospitals from across the UK. Eligible and …

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

RECOVERY Collaborative Group, PW Horby… - MedRxiv, 2021 - medrxiv.org
Background Treatment of COVID-19 patients with plasma containing anti-SARS-CoV-2
antibodies may have a beneficial effect on clinical outcomes. We aimed to evaluate the
safety and efficacy of convalescent plasma in patients admitted to hospital with COVID-19.
Methods In this randomised, controlled, open-label, platform trial (Randomised Evaluation of
COVID-19 Therapy [RECOVERY]) several possible treatments are being compared with
usual care in patients hospitalised with COVID-19 in the UK. Eligible and consenting …

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

DJ Dhasmana… - …, 2021 - research-repository.st-andrews.ac …
Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods:
This randomised, controlled, open-label, platform trial (Randomised Evaluation of COVID-19
Therapy [RECOVERY]), is assessing several possible treatments in patients hospitalised
with COVID-19 in the UK. Those trial participants with hypoxia (oxygen saturation< 92% on
air or requiring oxygen therapy) and evidence of systemic inflammation (C-reactive protein≥ …